Predictive value of FDG-PET in patients with advanced medullary thyroid cancer undergoing vandetanib treatment

被引：0
|
作者：
Werner, Rudolf [2 ,6 ]
Higuchi, Takahiro [4 ]
Muegge, Dirk [4 ]
Javadi, Mehrbod [3 ]
Fassnacht, Martin [5 ]
Buck, Andreas [4 ]
Lapa, Constantin [4 ]
Kreissl, Michael [1 ]
机构：
[1] Hosp Augsburg, Dept Nucl Med, Augsburg, Germany
[2] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, 600 N Wolfe St, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA
[4] Univ Hosp Wuerzburg, Dept Nucl Med, Wurzburg, Germany
[5] Univ Hosp WArzburg, Div Endocrinol & Diabet, Dept Internal Med 1, Wurzburg, Germany
[6] Univ Hosp WArzburg, Else KrAner Forschungskolleg, Dept Nucl Med, Wurzburg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The value of Ga-68 DOTA-TATE PET/CT scanning in the Assessment of Vandetanib Treatment Response in Advanced Medullary Thyroid Cancer
    Sahin, O. E.
    Asa, S.
    Khosroshahi, S. R.
    Uslu-Besli, L.
    Uslu, I.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S285 - S285
  • [22] Value of FDG-PET for breast cancer patients.
    Budinger, TF
    Bunker, SR
    Hawkins, RA
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 287P - 287P
  • [23] Predictive value of interim FDG-PET during neoajuvant chemotherapy in patients treated for locally advanced breast cancer.
    Musto, A.
    Zamagni, C.
    Ambrosini, V.
    Nanni, C.
    Rosati, M.
    Kumar, R.
    Alavi, A.
    Sansovini, M.
    Farsad, M.
    Montini, G.
    Franchi, R.
    Palucci, A.
    Pettinato, C.
    Castellucci, P.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S200 - S200
  • [24] Vandetanib—a new therapeutic option in advanced medullary thyroid cancer
    Linda Koch
    Nature Reviews Endocrinology, 2012, 8 (1) : 1 - 1
  • [25] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Keating, Gillian M.
    Lyseng-Williamson, Katherine A.
    Frampton, James E.
    BIODRUGS, 2012, 26 (06) : 431 - 435
  • [26] Vandetanib: A Guide to Its Use in Advanced Medullary Thyroid Cancer
    Gillian M. Keating
    Katherine A. Lyseng-Williamson
    James E. Frampton
    BioDrugs, 2012, 26 (6) : 431 - 435
  • [27] Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
    Ton, GiangThy N.
    Banaszynski, Megan E.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (10) : 849 - 855
  • [28] Efficacy and Toxicity of Vandetanib for Advanced Medullary Thyroid Cancer Treatment in Real Life Conditions
    Chougnet, Cecile N.
    Borget, Isabelle
    Tuthyref, Network
    Schlumberger, Martin Jean
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [29] Clinical value of whole body [18F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer
    Jiang, Jinjin
    Yang, Zhongyi
    Zhang, Yongping
    Xue, Jing
    Xu, Xiaoping
    Shi, Wei
    Hu, Silong
    Yao, Zhifeng
    Zhu, Beiling
    Li, Duanshu
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [30] Value of FDG-PET/CT for staging of locally advanced cervical cancer
    Barahona, Marc
    Marti, Lola
    Perlaza-Jimenez, Pilar
    Fernandez-Gonzalez, Sergi
    Torrejon, Juan Carlos
    Castilla, Mireia
    Vidal, August
    Najjari-Namal, Dina
    Stefanovic, Milica
    Pardo, Beatriz
    Gil-Martin, Marta
    Ponce, Jordi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A8 - A9
12345